Related Experiment Video
Updated: Jul 9, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Interventions in Hypertrophic Obstructive Cardiomyopathy
Wern Yew Ding1, Mohammed N Meah2, Rodney Stables2
1Liverpool Heart and Chest Hospital, Liverpool, United Kingdom; Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom.
Insights
Obstructive hypertrophic cardiomyopathy (oHCM) management is complex. This review details current and emerging percutaneous and surgical treatments for oHCM patients, aiming to clarify therapeutic options.
Area of Science:
- Cardiology
- Genetics
- Interventional Cardiology
Background:
- Obstructive hypertrophic cardiomyopathy (oHCM) is the most common inherited cardiomyopathy.
- oHCM leads to substantial morbidity and mortality.
- Current oHCM management strategies are not well-defined compared to other cardiac conditions.
Purpose of the Study:
- To review established and novel therapeutic interventions for obstructive hypertrophic cardiomyopathy.
- To focus on percutaneous and surgical treatment modalities for oHCM.
Main Methods:
- Literature review of established and novel interventions for oHCM.
- Discussion of surgical myectomy, mitral valve procedures, and percutaneous septal ablation.
- Exploration of device-based therapies and catheter ablation techniques.
Main Results:
- Surgical myectomy and mitral valve interventions are key surgical options.
- Percutaneous alcohol septal ablation and septal embolization are discussed.
- Radiofrequency ablation techniques, including percutaneous intramyocardial septal ablation, are reviewed.
Conclusions:
- A comprehensive range of percutaneous and surgical options exist for oHCM.
- Further research is needed to refine management guidelines for oHCM.
- Optimizing treatment strategies is crucial for improving outcomes in oHCM patients.
Abstract:
Obstructive hypertrophic cardiomyopathy is the most common genetically transmitted cardiomyopathy that is associated with significant morbidity and mortality. Despite contemporary treatments and interventions, the management of patients with obstructive hypertrophic cardiomyopathy remains poorly defined compared with other branches of cardiology. In this review, we discuss established and novel therapeutic interventions in patients with obstructive hypertrophic cardiomyopathy with a focus on percutaneous and surgical strategies including surgical myectomy, mitral valve repair or replacement, percutaneous alcohol septal ablation, pacemaker and cardioverter-defibrillator implantation, septal embolization, radiofrequency endocardial catheter ablation, and percutaneous intramyocardial septal radiofrequency ablation.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Diuretics
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

